Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palifermin - Amgen

Next Previous
X
Search
Drug Profile

Palifermin - Amgen

Alternative Names: AMJ 9701; Kepivance; Keratinocyte growth factor - Amgen; KGF - Amgen; Recombinant human fibroblast growth factor-7; Recombinant human keratinocyte growth factor; rhFGF-7; rHu-KGF; rhuFGF-7

Latest Information Update: 03 Dec 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Swedish Orphan Biovitrum
  • Class Chemoprotectants; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stomatitis
  • Discontinued Graft-versus-host disease; Inflammatory bowel diseases

Most Recent Events

  • 09 Apr 2021 Discontinued - Phase-II for Graft-versus-host disease in USA (IV) (Amgen pipeline, April 2021)
  • 09 Apr 2021 Discontinued - Preclinical for Inflammatory bowel diseases in USA (IV) (Amgen pipeline, April 2021)
  • 06 Dec 2016 No recent reports on development identified - Phase-II for Graft-versus-host disease in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top